GLPwatch

▾ Liraglutide for weight management.

Drug Ther Bull · 2017

Last updated 2026-05-28

Liraglutide, a GLP-1 drug sold as Saxenda, was approved in the UK in 2017 for weight management in adults when used alongside a reduced-calorie diet and increased physical activity. It is the first new weight-loss drug in the UK since orlistat, which had been the only option for many years.

AI summary of the abstract below.

JournalDrug Ther Bull, 2017
Citations1
Relative citation ratio0.03
NIH percentile4
Molecules liraglutide
Conditions studied Obesity

Abstract

Since 1950, 25 anti-obesity drugs have been withdrawn from use across the world, largely as a result of adverse effects. For several years, orlistat has been the only drug licensed in the UK for weight management. In January 2017, a new presentation of the glucagon-like peptide-1 (GLP-1) analogue liraglutide (▾Saxenda - Novo Nordisk) was launched in the UK as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults. Here, we review the evidence for its efficacy and safety and consider its place in managing people who are overweight or obese.

Verbatim abstract via PubMed 28701318 ↗

Related research